NCT06863272 2026-03-16
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
22 trialsNCT03460977 2026-03-13
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT05901649 2026-03-13
ArtemisPRO
Janssen-Cilag Ltd.
Active not recruiting
NCT03395197 2026-03-12
TALAPRO-2
Pfizer
Phase 3 Active not recruiting
NCT04821622 2026-03-11
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer
Phase 3 Active not recruiting
NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
NCT06136624 2026-03-11
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04221542 2026-03-06
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT07287150 2026-03-05
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT06551324 2026-03-04
MEVPRO-1
Pfizer
Phase 3 Recruiting
NCT06629779 2026-03-04
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
Phase 3 Recruiting
NCT07028853 2026-03-04
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT07230106 2026-03-03
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Recruiting
NCT06257693 2026-02-27
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
Alessa Therapeutics Inc.
Phase 1 Recruiting
NCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT05997615 2026-02-24
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06991556 2026-02-17
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT07226986 2026-02-17
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting